18-FDG
18-FDG is a pharmaceutical drug with 7 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 4 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
1
Mid Stage
1
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
100.0%
4 of 4 finished
0.0%
0 ended early
1
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Dual-targeting Tracer TATE-RGD for the Diagnosis of SSTR- and RGD- Positive Tumors
Effects of Fructose/Glucose-rich Diet on Brown Fat in Healthy Subjects (GB7)
TF-antigen Targeting Molecular Probe for PET Imaging in Solid Tumors
MMP14(MT1-MMP) Targeting Bicyclic Peptide Probe for PET Imaging in Solid Tumors
New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome
Clinical Trials (7)
A Dual-targeting Tracer TATE-RGD for the Diagnosis of SSTR- and RGD- Positive Tumors
Effects of Fructose/Glucose-rich Diet on Brown Fat in Healthy Subjects (GB7)
TF-antigen Targeting Molecular Probe for PET Imaging in Solid Tumors
MMP14(MT1-MMP) Targeting Bicyclic Peptide Probe for PET Imaging in Solid Tumors
New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome
18FDG-PET Imaging to Detect Changes in Airways Inflammation in Cystic Fibrosis Patients
The Role of Audiovisual Biofeedback on Image Quality During 4D Anatomic and Functional Imaging
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7